Amsterdam Molecular Therapeutics announces intention to launch an Initial Public Offering (IPO) on Euronext Amsterdam

Amsterdam, the Netherlands, May 22, 2007 - Amsterdam Molecular Therapeutics (AMT), a Dutch company active in the field of human gene therapy, is planning to raise new funds through an initial public offering (IPO) and to apply for admission of its shares to trading on Euronext Amsterdam's Eurolist by Euronext within the coming weeks.

AMT is a biopharmaceutical company that develops gene-based therapies for orphan diseases, for which no cure or at best symptomatic treatment is available. AMT’s products have the potential for a shortened time-to-market because regulatory authorities have streamlined the approval process for orphan diseases in order to better serve patients suffering from these diseases, thereby allowing orphan drugs to potentially get to market more quickly than drugs to treat non-orphan diseases.. AMT's lead product, AMT-011 to treat complete LPL deficiency, a very serious and rare metabolic disease, is currently in pre-registration clinical trials. In addition, AMT expects to start a combined Phase I/II study during the first quarter of 2008 for AMT-011 to treat a different indication, partial LPL deficiency occurring in the majority of patients with hyperlipoproteinemia type V.

The IPO is expected to consist of an offering of new shares which will be listed on Euronext Amsterdam's Eurolist by Euronext. AMT intends to use the proceeds of the IPO primarily for the development and commercialisation of its products and to build a specialized marketing and sales team for Europe and North America capable of selling AMT-011 for complete LPL deficiency, for which it expects to file for market authorization during the first quarter of 2008. ABN AMRO Rothschild and Kempen & Co are appointed as joint global coordinators and joint bookrunners.

This announcement is not an offer to sell or a solicitation of any offer to buy the securities of Amsterdam Molecular Therapeutics (AMT) Holding N.V. (the “Company”, and such securities, the “Securities”) in the United States or in any other jurisdiction.

The Securities have not been and will not be registered under the US Securities Act of 1933, as amended (the “Securities Act”) and may not be offered or sold in the United States unless registered under the Securities Act or an exemption from such registration is available. No public offering of Securities of the Company is being made in the United States.

This announcement does not constitute a prospectus. The offer to acquire securities pursuant to the proposed offering will be made, and any investor should make his investment, solely on the basis of information that will be contained in the prospectus to be made generally available in The Netherlands in connection with such offering. When made generally available, copies of the prospectus may be obtained at no cost through the website of Euronext Amsterdam (Dutch residents only).

This communication is directed at and distributed only to (i) persons outside the United Kingdom, or (ii) persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 or (iii) high net worth companies, unincorporated associations and partnerships and trustees of high value trusts as described in Article 49(2) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005. Any investment or investment activity to which this communication relates is available only to and will be engaged in only with such persons. This communication is confidential and is provided to recipients on a personal basis and must not be transferred or assigned or otherwise acted on or relied upon by persons within the United Kingdom who receive this communication (other than persons falling within (ii) and (iii) above).

- Ends -

About AMT

Amsterdam Molecular Therapeutics (AMT) B.V. (AMT) is a gene therapy company founded by scientists of the University of Amsterdam Medical Center (AMC) in 1998. AMT focuses on the development of gene-based therapies for orphan diseases. AMT’s long-term gene expression technology is based on specific delivery of therapeutic genes into target organs or tissues. Production of AAV-based gene therapy vectors has been optimized and AMT has developed and validated a unique, stable and scalable GMP production platform. Its lead product, AMT-011, is in pre-registration trials for the first indication: treatment of complete LPL deficiency.

The company's Management, Supervisory Board and Scientific Advisory Board bring together an extensive know-how from both gene science as well as the biotech and pharmaceutical worlds.

For further information, go to www.amtbv.com  or please contact

Northbank Communications

Adam Michael, Account Director

Phone: +44 20 7268 3002

Email: a.michael@northbankcommunications.com


Amsterdam Molecular Therapeutics BV

André Verwei, Chief Financial Officer

Phone: +31 (0)20 566 7394

Email: a.verwei@amtbv.com